Search
Pindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
International brands: Blockin L, Blocklin LMPI-674
go.drugbank.com/drugs/DB05749ExperimentalMPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.
Propiomazine
go.drugbank.com/drugs/DB00777ApprovedPropiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. … Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism.
Categories: Dopamine D2 Receptor AntagonistsIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Categories: Compounds used in a research, industrial, or household settingAVB-001
go.drugbank.com/drugs/DB18452InvestigationalAVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Loxoprofen
go.drugbank.com/drugs/DB09212ApprovedInvestigationalA transdermal preparation was approved for use in Japan in January 2006. … Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug.
DPI-221
go.drugbank.com/drugs/DB06121ExperimentalDPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.
Synonyms: .-((2S,5R)-2,5-DIMETHYL-4-(3-FLUOROBENZYL)-1-PIPERAZINYL)BENZYL)-N,N-DIETHYLBENZAMIDE, BENZAMIDE, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)-Peanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawnThe kernels are consumed roasted but a large percentage is used for the production of vegetable oil. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Synonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment